Replimune Group, Inc.
RP1 (vusolimogene oderparepvec)
advanced melanoma
Resolved
39days ago
Catalyst readout · May 29, 2026
What's at stake
A key catalyst for RP1 (vusolimogene oderparepvec) (advanced melanoma) is expected May 29, 2026.
Primary source
· SEC 8-K
verified 13h ago
“A copy of such news release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”